Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 4, 2015, Pages 437-444

  Iudici, Michele ^a   Cuomo, Giovanna ^a   Vettori, Serena ^a   Bocchino, Marialuisa ^b   Sanduzzi Zamparelli, Alessandro ^b   Cappabianca, Salvatore ^a   Valentini, Gabriele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Interstitial lung disease; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; DISEASE DURATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FEVER; FOLLOW UP; FORCED VITAL CAPACITY; HAIR LOSS; HEMATURIA; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG CAPACITY; MALE; MUSCLE CRAMP; MYALGIA; NAUSEA; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; COMPLICATION; DRUG COMBINATION; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; VITAL CAPACITY;

ADULT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84927665352     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.09.003     Document Type: Article

References (56)

1. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002, 81:139-153.
2. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
3. Silver R.M., Warrick J.H., Kinsella M.B., Staudt L.S., Baumann M.H., Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993, 20:838-844.
4. Tashkin D.P., Elashoff R., Clements P.J., Goldin J., Roth M.D., Furst D.E., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666.
5. Hoyles R.K., Ellis R.W., Wellsbury J., Lees B., Newlands P., Goh N.S., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006, 54:3962-3970.
6. Simeon-Aznar C.P., Fonollosa-Pla V., Tolosa-Vilella C., Selva O.C.A., Solans-Laque R., Palliza E., et al. Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. Open Respir Med J 2008, 2:39-45.
7. Akesson A., Scheja A., Lundin A., Wollheim F.A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994, 37:729-735.
8. Davas E.M., Peppas C., Maragou M., Alvanou E., Hondros D., Dantis P.C. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999, 18:455-461.
9. White B., Moore W.C., Wigley F.M., Xiao H.Q., Wise R.A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132:947-954.
10. Giacomelli R., Valentini G., Salsano F., Cipriani P., Sambo P., Conforti M.L., et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002, 29:731-736.
11. Griffiths B., Miles S., Moss H., Robertson R., Veale D., Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002, 29:2371-2378.
12. Pakas I., Ioannidis J.P., Malagari K., Skopouli F.N., Moutsopoulos H.M., Vlachoyiannopoulos P.G. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002, 29:298-304.
13. Airo P., Danieli E., Parrinello G., Antonioli C.M., Cavazzana I., Toniati P., et al. Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 2004, 22:573-578.
14. Ostojic P., Damjanov N. Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy. Clin Rheumatol 2006, 25:819-821.
15. Berezne A., Ranque B., Valeyre D., Brauner M., Allanore Y., Launay D., et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 2008, 35:1064-1072.
16. Yiannopoulos G., Pastromas V., Antonopoulos I., Katsiberis G., Kalliolias G., Liossis S.N., et al. Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 2007, 27:357-361.
17. Airo P., Danieli E., Rossi M., Frassi M., Cavazzana I., Scarsi M., et al. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 2007, 25:293-296.
18. Beretta L., Caronni M., Raimondi M., Ponti A., Viscuso T., Origgi L., et al. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol 2007, 26:168-172.
19. Wanchu A., Suryanaryana B.S., Sharma S., Sharma A., Bambery P. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. Int J Rheum Dis 2009, 12:239-242.
20. Tochimoto A., Kawaguchi Y., Hara M., Tateishi M., Fukasawa C., Takagi K., et al. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Mod Rheumatol 2011, 21:296-301.
21. Domiciano D.S., Bonfa E., Borges C.T., Kairalla R.A., Capelozzi V.L., Parra E., et al. A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clin Rheumatol 2011, 30:223-229.
22. Mittoo S., Wigley F.M., Wise R.A., Woods A., Xiao H., Hummers L.K. Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease. Open Rheumatol J 2011, 5:1-6.
23. Kowal-Bielecka O., Landewe R., Avouac J., Chwiesko S., Miniati I., Czirjak L., et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009, 68:620-628.
24. Nannini C., West C.P., Erwin P.J., Matteson E.L. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.
25. Poormoghim H., Moradi Lakeh M., Mohammadipour M., Sodagari F., Toofaninjed N. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatol Int 2012, 32:2431-2444.
26. Tashkin D.P., Elashoff R., Clements P.J., Roth M.D., Furst D.E., Silver R.M., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007, 176:1026-1034.
27. Martin-Suarez I., D'Cruz D., Mansoor M., Fernandes A.P., Khamashta M.A., Hughes G.R. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997, 56:481-487.
28. Paone C., Chiarolanza I., Cuomo G., Ruocco L., Vettori S., Menegozzo M., et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 2007, 25:613-616.
29. Valentini G., Paone C., La Montagna G., Chiarolanza I., Menegozzo M., Colutta E., et al. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 2006, 35:35-38.
30. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
31. LeRoy E.C., Medsger T.A. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28:1573-1576.
32. Walker U.A., Tyndall A., Czirjak L., Denton C., Farge-Bancel D., Kowal-Bielecka O., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group Database. Ann Rheum Dis 2007, 66:754-763.
33. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
34. Valentini G., Cuomo G., Abignano G., Petrillo A., Vettori S., Capasso A., et al. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 2011, 50:317-323.
35. Allanore Y., Meune C. N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. Clin Exp Rheumatol 2009, 27(3 Suppl. 54):59-63.
36. American Thoracic Society Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique-1995 update. Am J Respir Crit Care Med 1995, 152(6 Pt 1):2185-2198.
37. American Thoracic Society Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995, 152:1107-1136.
38. Goh N.S., Desai S.R., Veeraraghavan S., Hansell D.M., Copley S.J., Maher T.M., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177:1248-1254.
39. The BAL Cooperative Group Steering Committee Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 1990, 141(5 Pt 2):S169-S202.
40. Picillo U., Migliaresi S., Vatti M., Marcialis M.R., Ferruzzi A.M., Tirri G. Demographic differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1993, 36:1332-1334.
41. Steen V.D., Graham G., Conte C., Owens G., Medsger T.A. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992, 35:765-770.
42. Khanna D., Seibold J.R., Wells A., Distler O., Allanore Y., Denton C., et al. Systemic sclerosis-associated interstitial lung disease: lessons from clinical trials, outcome measures, and future study design. Curr Rheumatol Rev 2010, 6:138-144.
43. Daoussis D., Liossis S.N., Tsamandas A.C., Kalogeropoulou C., Kazantzi A., Sirinian C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010, 49:271-280.
44. Daoussis D., Liossis S.N., Tsamandas A.C., Kalogeropoulou C., Paliogianni F., Sirinian C., et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012, 30(2 Suppl. 71):S17-S22.
45. Khanna D., Saggar R., Mayes M.D., Abtin F., Clements P.J., Maranian P., et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011, 63:3540-3546.
46. Liossis S.N., Bounas A., Andonopoulos A.P. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006, 45:1005-1008.
47. Gerbino A.J., Goss C.H., Molitor J.A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008, 133(2):455-460.
48. Zamora A.C., Wolters P.J., Collard H.R., Connolly M.K., Elicker B.M., Webb W.R., et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008, 102:150-155.
49. Panopoulos S.T., Bournia V.K., Trakada G., Giavri I., Kostopoulos C., Sfikakis P.P. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung 2013, 191:483-489.
50. Furuya Y., Kuwana M. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. J Rheumatol 2011, 38:2186-2192.
51. Plastiras S.C., Vlachoyiannopoulos P.G., Tzelepis G.E. Mycophenolate mofetil for interstitial lung disease in scleroderma. Rheumatology (Oxford) 2006, 45:1572.
52. Haroon M., McLaughlin P., Henry M., Harney S. Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 2011, 5:299-304.
53. Derk C.T., Grace E., Shenin M., Naik M., Schulz S., Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 2009, 48:1595-1599.
54. Khanna D., Tseng C.-H., Farmani N., Steen V., Furst D., Clements P.J., et al. Clinical course of lung physiology in patients with Scleroderma and Interstitial Lung Disease. Analysis of the Scleroderma Lung Study placebo group. Arthritis Rheum 2011, 63:3078-3085.
55. Medsger T.A., Silman A.T., Steen V.D., Black C.M., Akesson A., Bacon P.A., et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999, 26:2159-2167.
56. Martinez F.J., McCune W.J. Cyclophosphamide for scleroderma lung disease. N Engl J Med 2006, 354:2707-2709.